Breast cancer resistance protein (Bcrp) is an ATP-dependent efflux drug transporter. It has a diverse spectrum of hydrophilic and hydrophobic substrates ranging from anticancer, antiviral and antihypertensive drugs, to organic anions, antibiotics, phytoestrogens (e.g., genistein, daidzein, coumestrol), xenoestrogens and steroids (e.g., dehydroepiandrosterone sulfate). Bcrp is an integral membrane protein in cancer and normal cells within multiple organs (e.g., brain, placenta, intestine and testis) that maintains cellular homeostasis by extruding drugs and harmful substances from the inside of cells. In the brain, Bcrp is a major component of the bloodbrain barrier located on endothelial cells near tight junctions (TJs). However, Bcrp is absent at the Sertoli cell blood-testis barrier (BTB); instead, it is localized almost exclusively to the endothelial TJ in microvessels in the interstitium and the peritubular myoid cells in the tunica propria. Recent studies have shown that Bcrp is also expressed stage specifically and spatiotemporally by Sertoli and germ cells in the seminiferous epithelium of rat testes, limited only to a testis-specific cell adhesion ultrastructure known as the apical ectoplasmic specialisation (ES) in stage VI-early VIII tubules. These findings suggest that Bcrp is equipped by late spermatids and Sertoli cells to protect late-stage spermatids completing spermiogenesis. Furthermore, Bcrp was found to be associated with F (filamentous)-actin and several actin regulatory proteins at the apical ES and might be involved in the organisation of actin filaments at the apical ES in stage VII-VIII tubules. These findings will be carefully evaluated in this brief review.
INTRODUCTION
Breast cancer resistance protein (Bcrp, also known as Abcg2, Mr ,70 kDa), as its name implies, was first discovered as an integral membrane protein and a multidrug resistance transporter in adriamycinresistant human MCF-7 (a human breast adenocarcinoma cell line) breast cancer cells approximately 15 years ago.
1,2 Bcrp is a multidrug resistance ATP-binding cassette (ABC) drug transporter-an efflux drug pump that utilizes ATP in transporting its substrates across the plasma membrane against a steep concentration gradient. Bcrp is a half transporter, as it requires dimerisation of two Bcrp polypeptides (Figure 1 ) to assemble into a fully functional efflux drug pump. It confers drug resistance by actively pumping chemotherapeutic drugs out of (or preventing their entry into) breast cancer cells, thereby making cancer cells highly resistant to chemotherapy drugs.
1,3-5 Bcrp, together with P-glycoprotein (Abcb1) and multidrug resistance-associated protein 1 (Mrp1) (Abcc1), constitute the ABC drug transporter family and since the discovery of P-glycoprotein in ovarian cancer cells some 35 years ago, Bcrp has been a major focus for cancer biologists in developing drug transporter inhibitors. 6, 7 However, after more than three decades of oncological work on ABC transporters focused on Bcrp, P-glycoprotein and Mrp1, in particular by developing inhibitors against these efflux drug pumps, we are still no closer to confirming the concept that chemotherapy efficacy can be improved by blocking transportermediated drug efflux. 8 This circumstance, at least in part, is due to the large number of drug transporters (.800 transporters) found in cancer cells. Many of these drug transporters are simultaneously expressed by cancer cells in all types of tumours. Interestingly, these three efflux transporters are not limited to cancer cells. Subsequent studies have shown that they are found in virtually all normal endothelial, epithelial and other cells in multiple organs, including the testes, [9] [10] [11] thus illustrating their roles in regulating normal cellular physiology. Nonetheless, P-glycoprotein and Bcrp are considered to be the two 'gatekeepers' of the blood-tumour barriers that limit the entry of anti-cancer drugs into tumour tissues, such as brain tumours. 12 While these drug transporters are present in the testes, few studies have examined the testes, and until recently virtually no functional studies, such as how they affect fluid composition in the testes, were found in the literature that examine their role in spermatogenesis. Our interest in studying drug transporters stems from our investigation of developing adjudin, 1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide, into a male contraceptive. [13] [14] [15] Although this compound is highly potent at disrupting germ cell adhesion in the testes, the drug was shown to have very limited bioavailability following oral administration. 16 Success in developing this compound into a male contraceptive relies heavily on our ability to prepare a better formulated version that is both economical to manufacture and that requires a low efficacy dose. 17 To achieve this goal, we need to better understand the role of drug transporters in determining the bioavailability of adjudin. Indeed, a knockdown of Pglycoprotein by RNAi has been shown to significantly improve the bioavailability of adjudin behind the Sertoli cell blood-testis barrier (BTB) with an increase in influx of [ 3 H]-adjudin across the Sertoli cell tight junction (TJ)-permeability barrier.
18 Surprisingly, a knockdown of Pglycoprotein was shown to impede the Sertoli cell TJ-barrier function by rendering the TJ-barrier more 'leaky'. 18 However, while a knockdown of drug influx pumps, such as organic anion transporting polypeptide 3 (Oatp3) (also known as Slco1a5, solute carrier organic anion transporter family member 1a5, an influx drug transporter; and a member of the SLC, solute carrier transporter, family), by RNAi also modulated the bioavailability of [ 3 H]-adjudin to the compartment behind the Sertoli cells, this knockdown, in contrast to P-glycoprotein, did not impede the TJ-barrier function. 19 Collectively, these findings suggest that the Sertoli cell TJ-barrier function, such as the TJ-permeability barrier, is closely associated with some of the efflux drug pumps, including P-glycoprotein.
In the testes, previous studies have shown that Bcrp is expressed mostly in endothelial cells of microvessels in the interstitium and in peritubular myoid cells in the tunica propria of both humans and mice 3,20,21 ( Figure 2) . Thus, Bcrp is not localized to the BTB in the testes. In this context, it is of interest to note that the BTB is composed of specialized junctions (e.g., basal ectoplasmic specialisation (ES) coexisting with TJs, and gap junctions, as well as desmosomes) 9, 22, 23 between adjacent Sertoli cells that are located near the basement membrane. The BTB also segregates the seminiferous epithelium into the basal and the adluminal compartments (Figure 2) . Unlike other blood-tissue barriers, [24] [25] [26] which are composed almost exclusively of capillary endothelial TJs, microvessels in the interstitium between seminiferous epithelium in the testes contribute virtually no barrier function to the BTB. [27] [28] [29] [30] However, in rodents, the peritubular myoid cell layer in the tunica propria that lies behind the basement membrane and the type I collagen layer was found to restrict the diffusion of lanthanum salt and colloidal carbon or thorium in ,75% of the tubules examined, 30, 31 making it a contributing component to the BTB. However, myoid cells are less effective at restricting diffusion of substances across the tunica propria in primates, 32 and perhaps humans. Thus, the BTB is contributed exclusively by Sertoli cells in the testes in primates, and most likely humans.
A recent study, however, showed that Bcrp, in addition to its predominant expression in the endothelial cells of microvessels in the interstitial space and peritubular myoid cells, is also expressed by Sertoli and germ cells, but restricted to the Sertoli/spermatid interface in the seminiferous epithelium known as apical ES (a testis-specific atypical adherens junction). 14, 25 Bcrp displays a restrictive spatiotemporal pattern of expression during the epithelial cycle, such that it is only detected at the apical ES in stage VI-VIII tubules, but not at stage IX-XIV or I-V (Figure 3) . 33 In short, unlike other drug transporters, such as P-glycoprotein and Oatp3, 34, 35 Bcrp is not a component of the Sertoli cell BTB, 33 but is stage specifically expressed by Sertoli cells and spermatid in addition to abundant expression by endothelial cells and peritubular myoid cells in rat testes. In this short review, we critically evaluate the likely role of Bcrp in the testes during spermatogenesis in light of these recent findings.
Bcrp-STRUCTURE AND FUNCTION

Structure
The membrane topology of Bcrp shown in Figure 1 illustrates that the 655-amino acid polypeptide (Mr ,70 kDa) is composed of six transmembrane domains, three extracellular domains, four intracellular domains and a nucleotide binding domain near its N-terminus. 36 However, this is only a half transporter, and a homodimerisation is necessary to create a functional Bcrp efflux pump.
Substrates
Bcrp has a wide spectrum of substrates including antibiotics, antiviral drugs, chemotherapeutic drugs (e.g., kinase inhibitors), dietary carcinogens (e.g., heterocyclic amines), HMG-CoA (or 3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors (drugs that block the enzyme HMG-CoA reductase which plays a central role in producing cholesterol in the liver), endogenous substances (e.g., steroids) and phytoestrogens ( Table 1 ), illustrating that Bcrp can actively pump these drugs/substances out of normal mammalian and cancer cells. In short, the list of .100 substrates of Bcrp is growing. It is known that Bcrp has the ability to transport the chemotherapeutic drug gefitinib, an inhibitor of EGFR tyrosine kinase, out of cells, and that multiple protein kinase inhibitors are substrates of Bcrp. 37 Furthermore, inhibition of phosphoinositide 3 kinase by wortmannin was found to induce translocation of Bcrp from the plasma membrane to cell cytosol, concomitant with a blockade of its transport activity in gall bladder cells. 38 Additionally, Bcrp interacts and co-localizes with Pim-IL, a Ser/Thr protein kinase. 39 Collectively, these findings suggest that Bcrp works closely with protein kinases for phosphorylation and dimerisation, affecting its transport ability and cellular localisation. Furthermore, Bcrp can actively pump dietary carcinogens (Table 1) out of epithelial cells, 40 which illustrates its protective significance. In addition, the list of phytoestrogens and xenoestrogens that are substrates of Bcrp is growing (Table 1) , illustrating its involvement in mediating the steroid microenvironment in the testes via localisation in the myoid cell layer in the testes (Figure 3 ). In fact, recent studies have shown that steroids, such as oestradiol-17b, testosterone and progesterone, can inhibit the transport activity of Bcrp and upregulate Bcrp expression and its cellular localisation in cancer cells, endothelial cells of the brain and endocrine organs. 21, 41, 42 Steroids, particularly testosterone and oestrogens, are known to regulate BTB and testicular Bcrp and spermatogenesis XJ Qian et al 456 function, [43] [44] [45] [46] and Bcrp plays a significant role in regulating the transport of steroids across the myoid cells and Sertoli cells at the apical ES (Table 1) . Additionally, the activity, expression and cellular distribution of Bcrp are regulated by steroids. 21, 41, 42 Collectively, these findings indicate an intimate physiological relationship between Bcrp and the androgen and/or oestrogen microenvironment in the testes, but there are no reports in the literature to assess the role of Bcrp in regulating the level of steroids in the seminiferous epithelium, interstitial fluid and/or the rete testis compartment. However, Bcrp 2/2 male mice are fertile, 47 even though these mice display a malfunction in the disposition of phytoestrogens (e.g., genistein, daidzein, coumestrol), 48 suggesting that while it is important to testicular function, its loss in function via deletion in male mice can be superseded by other ABC drug transporters, such as P-glycoprotein and Mrp1. Nevertheless, even if the efficacy of spermatogenesis is reduced by 90% (men produce upwards of 100 million sperm each day after puberty), rodents and men can remain fertile. 49 Thus, it may be important to re-examine whether there are defects in spermatogenesis in these Bcrp 2/2 mice and whether the steroidal contents in the testes of these mice are different from those of wild-type mice.
LOCALISATION OF Bcrp IN THE TESTIS-AN UNEXPECTED TURN OF EVENTS Expression and stage-specific localisation
In the testes, this integral membrane protein is localized predominantly in the endothelial cells of the microvessels in the interstitial space and in peritubular myoid cells in the tunica propria (Figure 3 ) Figure 3 A study by dual-labelled immunofluorescence analysis to examine the cellular localisation and stage-specific expression of Bcrp in the seminiferous epithelium of rat testes. (a) Bcrp, unlike other efflux (e.g., P-glycoprotein) 51 and influx (e.g., Oatp3) 19 drug transporters, is not found at the Sertoli cell BTB near the basement membrane as illustrated. Instead, Bcrp (red fluorescence) was detected at the tunica propria associated with peritubular myoid cells (see 'yellow' arrowheads), Leydig cells (see 'red' arrowheads) and most notably with endothelial cells of the microvessels in the interstitium (see 'white' arrowheads annotating a microvessel in which Bcrp (red fluorescence) was found to colocalize with F-actin (green fluorescence) in the microvessel). Interestingly, Bcrp was also detected at the Sertoli/spermatid interface in an ultrastructure known as the apical ES (a testisspecific adherens junction), beginning in late stage VI, most predominantly in stage VII, as shown here, gradually diminishing by stage VIII, and was virtually nondetectable in stage IX. In short, its expression at the apical ES is stage-specific during the epithelial cycle, confined to stages VII-VIII. (b) This experiment clearly illustrates Bcrp is not a component of the Sertoli cell BTB as Bcrp failed to colocalize with the tight junction adaptor protein ZO-1 and other BTB-associated proteins (e.g., N-cadherin). 33 Dual-labelled immunofluorescence analysis was performed as previously described. 33 Mouse anti-Bcrp antibody was obtained from Kamiya Biomedical Co. (Seattle, WA, USA; Cat. # MC-177) and used at a 1 : 50 dilution. Rabbit anti-ZO-1 was obtained from Invitrogen Life Technologies (Grand Island, NY, USA; Cat. # 61-7300) and used at a 1 : 100 dilution. Phalloidin-FITC was obtained from Sigma-Aldrich (St Louis, MO, USA; Cat. # P5282) and used at a 1 : 70 dilution. Scale bar in a is 50 mm, or 10 mm in the inset and the magnified micrograph of the corresponding boxed area, which applies to other micrographs in b. The scale bar in b is 10 mm, which applies to other micrographs in this panel. Bcrp, breast cancer resistance protein; BTB, blood-testis barrier; ES, ectoplasmic specialisation; Oatp3, organic anion transporting polypeptide 3. The BTB anatomically divides the seminiferous epithelium into the basal and the adluminal (apical) compartments. The non-cellular (i.e., basement membrane, type I collagen layer) and cellular (peritubular myoid cells, lymphatic endothelium) zones of the tunica propria are also shown. Different cell junctions in the epithelium between the Sertoli and germ cells are also shown. Bcrp is highly expressed by the endothelial cells of the microvessels in the interstitium and the peritubular myoid cells of the tunica propria behind the basement membrane and the type I collagen layer. However, Bcrp is also expressed by elongated spermatids and Sertoli cells at the apical ES, though it is limited to stage VI-VIII tubules and is predominantly expressed in stage VII tubules. Bcrp, breast cancer resistance protein; BTB, blood-testis barrier; ES, ectoplasmic specialisation; GJ, gap junction; TJ, tight junction.
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as reported previously. 20, 21, 48 Unlike P-glycoprotein, which is localized to the BTB and expressed by Sertoli cells, Leydig cells and late spermatids, 20, 50, 51 and Mrp1, which is also localized to Sertoli cells at the BTB in humans and mice, 20, 52 , but not in endothelial cells in the microvessels of rat testes, 53 Bcrp is not found at the BTB in rat testes. 20, 21, 33 Recent studies have shown that Bcrp is also expressed by Sertoli cells and late spermatids (steps 17-18, but not step 19) in rat testes in a tightly stage-specific pattern at the Sertoli/spermatid interface at the apical ES, in stage VI-VIII tubules (Figure 3) . 33 Bcrp is a component of the apical ES A recent study showed that Bcrp structurally interacts with actin and actin-related protein 3 (Arp3), which together with Arp2 form the Arp2/3 complex. This in turn creates a seven-subunit complex with actin-related protein 2/3 complex component 1 to 5 and, when it is activated by neuronal Wiskott-Aldrich syndrome protein, induces branched actin polymerisation that is capable of converting the actin filament bundles at the apical ES from their 'bundled' to a 'de-bundled/ branched' configuration, destabilizing the apical ES function 54, 55 in adult rat testes. 33 Bcrp also structurally interacts with epidermal growth factor receptor pathway substrate 8 (Eps8), an actin barbed end capping and bundling protein capable of maintaining the actin filament bundles at the apical ES to confer spermatid adhesion and polarity, 54, 55 which illustrates that Bcrp may be involved in F-actin reorganisation at the apical ES. Bcrp is localized mostly to the concave side of the spermatid head in stage VI-VII tubules at the apical ES. It first appears at the apical ES in stage VI tubules, is prominently expressed in stage VII tubules, and its expression rapidly diminishes in stage VIII of the epithelial cycle (Figure 3) . 33 It is noted that the apical ES is an F-actin-rich testis-specific adherens junction, in which bundles of actin filaments that lie perpendicular to the plasma membrane of the Sertoli cell are sandwiched between cisternae of endoplasmic reticulum and the apposing Sertoli-spermatid plasma membrane. 14, 46, 56 Once the apical ES appears in step 8 spermatids during spermiogenesis, it is the only anchoring device, replacing desmosomes and gap junctions. It persists until step 19 spermatids when mature spermatozoa are released into the tubule lumen at spermiation. 46, 56, 57 Thus, the identification of Bcrp and its association with Eps8 and Arp3 suggest that Bcrp is involved in regulating F-actin organisation, converting actin filaments from their bundled configuration to a branched network, thereby destabilizing the apical ES adhesion function. 54, 55 This phenomenon seems to suggest that Bcrp may be involved in other yet-to-be defined functions during spermatogenesis. Furthermore, the concave side of the spermatid heads in stage VII tubules was recently shown to be the site where extensive endocytic vesicle-mediated protein trafficking occurs, [58] [59] [60] so that 'old' apical ES proteins (e.g., b1-integrin, nectin-3, laminin-a3, -b3 and -c3 chains) can be endocytosed and recycled to the newly arisen apical ES in step 8 spermatids during spermiogenesis at stage VIII of the epithelial cycle. 46, 61 Nonetheless, the finding that Bcrp is expressed stage specifically by late spermatids in the adluminal compartment 33 has shown that this efflux drug pump may be used by late-stage spermatids to safeguard their development by pumping out unwanted substances in the adluminal compartment prior to their transformation to mature spermatozoa. This possibility must be carefully evaluated in future studies.
FUNCTIONAL SIGNIFICANCE OF Bcrp IN SPERMATOGENESIS
As noted above, unlike other efflux (e.g., P-glycoprotein) 18, 51 and influx (e.g., Oatp3) drug transporters 19 that are present at the BTB, most notably at the Sertoli/Sertoli cell interface near the basement membrane and colocalized with adhesion protein complexes (e.g., occludin-ZO-1, N-cadherin-b-catenin, JAM-A-ZO-1) at the BTB, Bcrp is absent at the BTB and does not colocalize with any BTB-associated cell adhesion protein complexes. 33 Instead, Bcrp is restricted to the endothelium of the microvessels in the interstitial space (Figure 3) and is also detected in peritubular myoid cells in the tunica propria and Leydig cells. 33 Interestingly, Bcrp is also found at the apical ES at the Sertoli cellelongating/elongated spermatid interface expressed by Sertoli cells and spermatids and is upregulated stage specifically at the apical ES during stage VII. 33 In short, Bcrp first appears at the apical ES in late stage VI, is highly expressed in stage VII, but is considerably diminished in stage VIII and virtually non-detectable in stage IX (Figure 3) , 33 thus illustrating that this drug efflux transporter is somehow involved in protecting late-stage spermatids (steps 17-19) (or a mechanism being used by late stage spermatids) by sequestering any unwanted toxicants/ drugs from perturbing the final stage of spermiogenesis. More importantly, Bcrp was shown to associate with Eps8, Arp3 and actin at the apical ES, 33 and a knockdown of Bcrp by RNAi was found to perturb spermatid polarity and adhesion via changes in the localisation of Eps8 and Arp3 at the apical ES in stage VII tubules. These actin regulatory proteins moved away from the apical ES, and their mislocalisation 36, 37, 62, 63 Bcrp and spermatogenesis XJ Qian et al 458 led to changes in the F-actin distribution at the apical ES, thus rendering a disruption of spermatid polarity. 33 For instance, following the in vivo knockdown of Bcrp by RNAi, F-actin at the apical ES of rats in the treatment vs. the control group was considerably reduced, indicating that actin filaments no longer retained their 'bundled' configuration, but 'de-bundled' via a down-regulation and mislocalisation of Eps8. 33 These findings illustrate that Bcrp may be involved in the organisation of F-actin at the apical ES during spermiogenesis. However, more work is needed to expand this initial observation regarding the precise molecular mechanism(s) by which Bcrp regulates F-actin organisation in the epithelium during the epithelial cycle. Based on these findings, we now provide a hypothetical model regarding the likely function of Bcrp in the seminiferous epithelium of rat testes as shown in Figure 4 . It is obvious that this model will be rapidly updated when more data are available from future studies.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
In this brief review, we have critically evaluated the likely functional significance of Bcrp in spermatogenesis in light of its unusual cellular distribution and stage-specific expression patterns in the seminiferous epithelium during the epithelial cycle of spermatogenesis. We have also provided a hypothetical model of the likely involvement of Bcrp in regulating apical ES function via its effects on the F-actin network at the ES, mediated by Eps8 and Arp3 in stage VII-VIII tubules, in addition to its normal role of serving as a drug efflux transporter. This hypothesis is supported by functional experiments using RNAi that demonstrated the likely involvement of Bcrp in the organisation of F-actin at the apical ES during spermiogenesis. Further work is warranted to explore the functional significance of this efflux drug transporter in spermatogenesis. For instance, the functional involvement of Bcrp in steps 18-19 spermatids as well as Sertoli cells in stage VI-VIII tubules in excluding drugs, such as adjudin, from the epithelium must be carefully evaluated. This goal may be accomplished by evaluating the ability of staged tubules isolated from rats to transport adjudin across the seminiferous tubule into the tubule lumen.
AUTHOR CONTRIBUTIONS
CYC conceived the ideas for preparing this review article, wrote the first draft, and revised and prepared the final version of the manuscript. CYC, XQ and YHC performed the literature search, research on Bcrp and other drug transporters and critically evaluated findings in the field. YHC and CYC prepared Table 1 . CYC, DDM and XQ critically discussed and evaluated the latest research on the subject of drug transporters, in particular Bcrp. CYC conceived the hypothetical model of Bcrp function at the apical ES. XQ and CYC provided the first draft of the hypothetical model. XQ prepared all the figures. CYC, XQ and YHC performed the final editing of the manuscript.
COMPETING FINANCIAL INTERESTS
The authors have nothing to declare. It is conceivable that Bcrp functions as a drug efflux transporter at all stages of the epithelial cycle and is highly expressed by peritubular myoid cells at the tunica propria and by endothelial cells of the microvessels in the interstitium to prevent the entry of unwanted drugs and/or toxicants that would otherwise perturb spermatogenesis into the seminiferous epithelium. (a) In a stage VII tubule, Bcrp, in addition to serving as an efflux drug transporter to pump harmful substances out of the elongated spermatids (step 19) and Sertoli cells, is highly expressed at the apical ES and may be used to recruit Eps8 to the apical ES to maintain F-actin integrity. Accordingly, actin filament bundles can be properly organized to confer apical ES function given that Bcrp was found to structurally interact with Eps8 and because its knockdown in the testes, in vivo by RNAi, was shown to perturb F-actin organisation at the apical ES in stage VII tubules (see text for details). However, during stage VIII of the cycle, Bcrp may be involved in the recruitment of Arp3 to the apical ES to induce branched actin polymerisation. Thus, actin filament bundles can be 'debundled' and re-organized as a branched actin network. This destabilisation of the apical ES facilitates (i) the release of sperm at spermiation and (ii) endocytic vesicle-mediated protein trafficking so that apical ES proteins can be transcytosed and recycled to assemble 'new' apical ES that arise from spermiogenesis, such as at the interface of step 8 spermatids and Sertoli cells in stage VIII tubules. (b) Bcrp was not found to be expressed by Sertoli cells at the BTB in stage VII-VIII tubules nor in any other stages of the epithelial cycle. However, Bcrp is restricted to the endothelial cells of the microvessels in the interstitium and to the peritubular myoid cells at the tunica propria during both stages to prevent drugs/ toxicants from entering the seminiferous epithelium and perturbing spermatogenesis. As Bcrp is absent at the BTB, Bcrp does not appear to be involved in the restructuring of the F-actin network at the basal ES in stage VIII tubules. Arp3, actin-related protein 3; Bcrp, breast cancer resistance protein; BTB, blood-testis barrier; Eps8, epidermal growth factor receptor pathway substrate 8; ES, ectoplasmic specialisation.
Bcrp and spermatogenesis XJ Qian et al 459
Asian Journal of Andrology
